Microscopical Variables and Tumor Inflammatory Microenvironment Do Not Modify Survival or Recurrence in Stage I-IIA Lung Adenocarcinomas
Author:
Dell’Amore Andrea1, Bonis Alessandro1ORCID, Melan Luca1, Silvestrin Stefano1, Cannone Giorgio1ORCID, Shamshoum Fares1, Zampieri Alberto1ORCID, Pezzuto Federica2ORCID, Calabrese Fiorella2, Nicotra Samuele1, Schiavon Marco1, Faccioli Eleonora1, Mammana Marco1, Comacchio Giovanni Maria1, Pasello Giulia3, Rea Federico1
Affiliation:
1. Thoracic Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health–DSCTV, University of Padova, 35128 Padova, Italy 2. Pathology Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health–DSCTV, University of Padova, 35128 Padova, Italy 3. Oncology 2 Unit, Veneto Institute of Oncology IOV–IRCCS, 35128 Padova, Italy
Abstract
Microscopical predictors and Tumor Immune Microenvironment (TIME) have been studied less in early-stage NSCLC due to the curative intent of resection and the satisfactory survival rate achievable. Despite this, the emerging literature enforces the role of the immune system and microscopical predictors as prognostic variables in NSCLC and in adenocarcinomas (ADCs) as well. Here, we investigated whether cancer-related microscopical variables and TIME influence survival and recurrence in I-IIA ADCs. We retrospectively collected I-IIA ADCs treated (lobectomy or segmentectomy) at the University Hospital (Padova) between 2016 and 2022. We assigned to pathological variables a cumulative pathological score (PS) resulting as the sum of them. TIME was investigated as tumor-infiltrating lymphocytes (TILs < 11% or ≥11%) and PD-L1 considering its expression (<1% or ≥1%). Then, we compared survival and recurrence according to PS, histology, TILs and PD-L1. A total of 358 I-IIA ADCs met the inclusion criteria. The median PS grew from IA1 to IIA, indicating an increasing microscopical cancer activity. Except for the T-SUVmax, any pathological predictor seemed to be different between PD-L1 < 1% and ≥1%. Histology, PS, TILs and PD-L1 were unable to indicate a survival difference according to the Log-rank test (p = 0.37, p = 0.25, p = 0.41 and p = 0.23). Even the recurrence was non-significant (p = 0.90, p = 0.62, p = 0.97, p = 0.74). According to our findings, resection remains the best upfront treatment in I-IIA ADCs. Microscopical cancer activity grows from IA1 to IIA tumors, but it does not affect outcomes. These outcomes are also unmodified by TIME. Probably, microscopical cancer development and immune reaction against cancer are overwhelmed by an adequate R0-N0 resection.
Subject
Cancer Research,Oncology
Reference33 articles.
1. Garinet, S., Wang, P., Mansuet-Lupo, A., Fournel, L., Wislez, M., and Blons, H. (2022). Updated Prognostic Factors in Localized NSCLC. Cancers, 14. 2. Rami-Porta, R. (2021). Future Perspectives on the TNM Staging for Lung Cancer. Cancers, 13. 3. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies;Galon;Nat. Rev. Drug Discov.,2019 4. Predictive biomarkers for checkpoint inhibitor-based immunotherapy;Gibney;Lancet Oncol.,2016 5. Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: The genetic front;Saigi;Oncogene,2019
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|